Drugs / HM12460A
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03332836 | Oct 2017 → Jan 2019 | type 2 diabetes mellitus | Hanmi Pharmaceutical Company Limited | Terminated | No outcome recorded |
| Phase 1 | NCT03330314 | Oct 2017 → Feb 2018 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT01724814 | Dec 2012 → Jul 2014 | type 1 diabetes mellitus, type 2 diabetes mellitus | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HM12460A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01724814 ↗ |
| Modality | Protein / enzyme biologic | “novel very-long acting insulin formulation (HM12460A)” NCT01724814 ↗ |
| Route | Subcutaneous | “Single dose SC administration” NCT01724814 ↗ |